205 related articles for article (PubMed ID: 9777893)
1. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Matthews DC
Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
[TBL] [Abstract][Full Text] [Related]
3. Antibody-targeted therapy for myeloid leukemia.
Appelbaum FR
Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
5. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Caron PC; Dumont L; Scheinberg DA
Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
[TBL] [Abstract][Full Text] [Related]
6. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
[TBL] [Abstract][Full Text] [Related]
7. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
8. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
[TBL] [Abstract][Full Text] [Related]
9. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.
Appelbaum FR; Matthews DC; Eary JF; Badger CC; Kellogg M; Press OW; Martin PJ; Fisher DR; Nelp WB; Thomas ED
Transplantation; 1992 Nov; 54(5):829-33. PubMed ID: 1440849
[TBL] [Abstract][Full Text] [Related]
10. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
Caron PC; Scheinberg DA
Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
[TBL] [Abstract][Full Text] [Related]
13. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for acute myeloid leukemia.
Jurcic JG
Curr Oncol Rep; 2005 Sep; 7(5):339-46. PubMed ID: 16091194
[TBL] [Abstract][Full Text] [Related]
15. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
[TBL] [Abstract][Full Text] [Related]
16. [Antibody directed therapy for leukemia].
Takeshita A; Naito K; Ohno R
Nihon Rinsho; 2002 Mar; 60(3):517-24. PubMed ID: 11904967
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates.
Sievers EL
Curr Opin Oncol; 2000 Jan; 12(1):30-5. PubMed ID: 10687726
[TBL] [Abstract][Full Text] [Related]
18. Immunobiologic therapies for myelodysplastic syndrome.
Appelbaum FR
Best Pract Res Clin Haematol; 2004 Dec; 17(4):653-61. PubMed ID: 15494301
[TBL] [Abstract][Full Text] [Related]
19. Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
Jurcic JG
Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody therapy in acute myeloid leukemia.
Feldman EJ
Curr Hematol Rep; 2003 Jan; 2(1):73-7. PubMed ID: 12901157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]